Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

Sutro Biopharma

12/08/2026 16:01

Sutro Biopharma Inc STRO.OQ reported a quarterly adjusted loss of $2.33​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.40.  The mean expectation of fourteen analysts for the quarter was for a loss of $2.19 per share. Wall Street expected results to range from $-2.63 to $-1.55 per share.
Revenue fell 84.6% to $9.84 million from a year ago; analysts expected $13.05 million. 
Sutro Biopharma Inc's reported EPS for the quarter was a loss of $2.33​.
The company reported a quarterly loss of $38.53 million.
Sutro Biopharma Inc shares had fallen by 24.6% this quarter and gained 116.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 30.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Sutro Biopharma Inc is $50.00, about 49.9% above its last closing price of $25.04
This summary was machine generated from LSEG data August 12 at 03:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-2.19
-2.33
Missed
Mar. 31 2026 
-3.77
-2.94
Beat
Dec. 31 2025 
-4.34
-5.29
Missed
Sep. 30 2025 
-4.14
-6.70
Missed